Tracheal Aspirate and Bronchoalveolar Lavage as Potential Specimen Types for COVID-19 Testing Using the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV

被引:8
|
作者
Kim, Sang Ho [1 ]
AlMutawa, Fatimah [2 ,3 ]
机构
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Western Univ, Dept Pathol & Lab Med, London, ON, Canada
[3] London Hlth Sci Ctr, London, ON, Canada
来源
MICROBIOLOGY SPECTRUM | 2022年 / 10卷 / 03期
关键词
SARS-CoV-2; multiplex; lower respiratory tract specimen; COVID-19; Xpert Xpress SARS-CoV-2 assay;
D O I
10.1128/spectrum.00399-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Xpert Xpress SARS-CoV-2/Flu/RSV is a rapid diagnostic test currently approved for the detection of SARS-CoV-2 using upper respiratory tract specimens. This study attempts to assess the performance of this assay using upper and lower respiratory tract specimens by comparing its results to the lab-developed PCR test. We assessed the performance of GeneXpert for the detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus for upper respiratory tract specimens. In addition, the SARS-CoV-2 detection was evaluated for lower respiratory tract specimens (bronchoalveolar lavage and tracheal aspirate). Precision and reproducibility of the test were also assessed using samples with varying cycle threshold values. Xpert Xpress SARS-CoV-2/Flu/RSV shows 100% positive and negative agreements for all four targets when tested using upper respiratory tract specimens. For lower respiratory tract specimens, tracheal aspirate and bronchoalveolar lavage samples respectively show 96% and 100% positive percent agreement for SARS-Cov-2 target only. No positive flu/RSV samples were included for lower respiratory tract specimens. Both samples show 100% negative percent agreement. The precision and reproducibility assay also showed 100% correspondence. Xpert Xpress SARS-CoV-2/Flu/RSV can be potentially used for SARS-Cov-2 detection in lower respiratory tract specimens. Performance passed our study acceptance criteria and shows promising implications as a point of care detection assay. IMPORTANCE Cepheid's Xpert Xpress SARS-CoV-2/Flu/RSV provides a means of rapid diagnosis that can help in hospital bed management and patient flow. It is also important for each microbiology lab to increase its capacity and most importantly have a different platform to overcome the anticipated reagent shortage at times of peak community transmission. There is limited evidence on using it for lower respiratory tract specimens. Here we present our validation for upper respiratory tract specimens as well as a potential use for lower respiratory specimens (BAL and TA), and we discuss some of the applications we have been using in our organization. Cepheid's Xpert Xpress SARS-CoV-2/Flu/RSV provides a means of rapid diagnosis that can help in hospital bed management and patient flow. It is also important for each microbiology lab to increase its capacity and most importantly have a different platform to overcome the anticipated reagent shortage at times of peak community transmission.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Evaluation of the analytical and clinical performance of two RT-PCR based point-of-care tests; Cepheid Xpert ® Xpress CoV-2/Flu/RSV plus and SD BioSensor STANDARD™ M10 Flu/RSV/SARS-CoV-2
    Jensen, Christel Barker
    Schneider, Uffe Vest
    Madsen, Tina Vasehus
    Nielsen, Xiaohui Chen
    German, Chih Man
    Severinsen, Jette Krogh
    Hoegh, Anne Mette
    Botnen, Amanda Bolt
    Trebbien, Ramona
    Lisby, Jan Gorm
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2024, 172
  • [22] Pooling samples to increase testing capacity with Xpert Xpress SARS-CoV-2 during the Covid-19 pandemic in Lao People's Democratic Republic
    Iem, Vibol
    Xangsayarath, Phonepadith
    Chittamany, Phonenaly
    Suthepmany, Sakhone
    Siphanthong, Souvimone
    Paboriboune, Phimpha
    Somphavong, Silaphet
    Konstantina, Kontogianni
    Khan, Jahangir A. M.
    Edwards, Thomas
    Wingfield, Tom
    Creswell, Jacob
    Dominguez, Jose
    Cuevas, Luis E.
    [J]. PLOS ONE, 2022, 17 (09):
  • [23] Using SARS-CoV-2 Antibody Testing in COVID-19 Research
    Amraotkar, Alok R.
    Keith, Rachel J.
    Palmer, Kenneth E.
    Bhatnagar, Aruni
    [J]. AMERICAN JOURNAL OF MEDICINE, 2023, 136 (06): : 501 - 503
  • [24] Initiation of COVID-19 Testing by Cartridge-Based Nucleic Acid Amplification Test (Cepheid Xpress SARS-CoV-2): Our Experience at a Zonal Hospital
    Shukla, Rajat
    Bhalla, Gurpreet Singh
    [J]. JOURNAL OF MARINE MEDICAL SOCIETY, 2020, 22 (03) : 135 - 136
  • [25] Asymptomatic Patient Testing After 10:1 Pooling Using the Xpert Xpress SARS-CoV-2 Assay
    Procop, Gary W.
    Tuohy, Marion
    Ramsey, Christine
    Rhoads, Daniel D.
    Rubin, Brian P.
    Figler, Richard
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 155 (04) : 522 - 526
  • [26] Covid-19: Researchers call for routine flu testing of hospital inpatients with SARS-CoV-2 infection
    Wise, Jacqui
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2022, 376 : o809
  • [27] Ignoring SARS-CoV-2 testing performance during COVID-19
    Buchta, Christoph
    Zeichhardt, Heinz
    Griesmacher, Andrea
    Schellenberg, Ingo
    Kammel, Martin
    [J]. LANCET MICROBE, 2023, 4 (05): : E296 - E296
  • [28] ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
    Fragkou, Paraskevi C.
    De Angelis, Giulia
    Menchinelli, Giulia
    Can, Fusun
    Garcia, Federico
    Morfin-Sherpa, Florence
    Dimopoulou, Dimitra
    Mack, Elisabeth
    de Salazar, Adolfo
    Grossi, Adriano
    Lytras, Theodore
    Skevaki, Chrysanthi
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (06) : 812 - 822
  • [29] SARS-CoV-2 in semen: Potential for sexual transmission in COVID-19
    Sharun, Khan
    Tiwari, Ruchi
    Dhama, Kuldeep
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2020, 84 : 156 - 158
  • [30] SARS-COV-2 as potential microRNA sponge in COVID-19 patients
    Li, Chang
    Wang, Rebecca
    Wu, Aurora
    Yuan, Tina
    Song, Kevin
    Bai, Yongsheng
    Liu, Xiaoming
    [J]. BMC MEDICAL GENOMICS, 2022, 15 (SUPPL 2)